Drug intelligence / Profile preview

EGFR-TKI + crizotinib

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of an EGFR tyrosine kinase inhibitor (such as osimertinib, erlotinib, afatinib, or gefitinib) and crizotinib, a MET inhibitor. This combination is primarily used to overcome MET amplification-mediated resistance to EGFR-TKI therapy in non-small cell lung cancer (NSCLC) patients with activating EGFR mutations.

Targets

ROS1 (Proto-oncogene tyrosine-protein kinase ROS)MET (Mesenchymal-epithelial transition factor receptor)ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on EGFR-TKI + crizotinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EGFR-TKI + crizotinib.

Explore the full profile